DDInter1309 DDInter1376
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nizatidine {u} (Compound) resembles {v} (Compound) Ranitidine
Nizatidine {u} (Compound) binds {v} (Gene) HRH2
Nizatidine {u} (Compound) upregulates {v} (Gene) RAB27A
Nizatidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Nizatidine {u} (Compound) downregulates {v} (Gene) SLC35B1
Nizatidine {u} (Compound) causes {v} (Side Effect) Sinusitis
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flurbiprofen
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Nizatidine (Compound) resembles Ranitidine (Compound)
Nizatidine (Compound) binds HRH2 (Gene)
Nizatidine (Compound) upregulates RAB27A (Gene)
Nizatidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Nizatidine (Compound) downregulates SLC35B1 (Gene)
Nizatidine (Compound) causes Sinusitis (Side Effect)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib